No Data
16 New GLP-1 Weight-loss Drugs Could Be Launched by 2029: Report
Johnson & Johnson Phase 2 Trial of Potential Lung Cancer Treatment Meets Primary Endpoint
Express News | J&J -Additional Studies Are Ongoing to Evaluate Prophylactic Strategies to Reduce Irrs for Patients Receiving IV Rybrevant
Express News | J&J -Showed That Prophylaxis With 8-Mg Dexamethasone Taken for Two Days Prior to First Infusion Met Primary Endpoint of Incidence of Irrs at C1D1
Express News | J&J: Safety Profile of Rybrevant(®) and Lazcluze™ With Prophylactic Dexamethasone at Initiation of Treatment Consistent With Previous Studies
Express News | J&J: Dexamethasone Pre-Medication Regimen Showed an Infusion-Related Reaction Rate of 22.5% With Intravenous Rybrevant
No Data
